Regulatory & Safety Aspects of Cell & Gene Therapy

Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.

    Related Conference of Regulatory & Safety Aspects of Cell & Gene Therapy

    June 16-17, 2025

    21st Global Summit on Stem Cell & Regenerative Medicine

    Frankfurt, Germany
    July 21-22, 2025

    18th World Congress on Stem Cell Research

    Barcelona, Spain
    September 25-26, 2025

    6th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada

    Regulatory & Safety Aspects of Cell & Gene Therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in